Bloodstream Infections in Hospitalized Children: Epidemiology and Antimicrobial Susceptibilities

Beatriz Larru1, Wu Gong, Neika Vendetti

  • 1From the *Division of Infectious Diseases, Center of Pediatric Clinical Effectiveness, †Health Care Analytics Unit, Center of Pediatric Clinical Effectiveness, ‡Pathology & Laboratory Medicine, The Children's Hospital of Philadelphia, Pennsylvania; §Department of Biostatistics and Epidemiology, and ¶Center for Clinical and Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Insights

Bloodstream infections in children are often caused by Gram-positive and ESKAPE pathogens. Antimicrobial resistance patterns were favorable, but ongoing surveillance is crucial for tracking emerging resistance trends.

Area of Science:

  • Pediatric Infectious Diseases
  • Clinical Microbiology
  • Antimicrobial Resistance

Background:

  • Bloodstream infections (BSI) significantly contribute to child morbidity and mortality.
  • Existing BSI epidemiology and resistance data primarily derive from adult hospitalized populations.
  • Understanding pediatric-specific BSI patterns is critical for effective treatment and public health.

Purpose of the Study:

  • To investigate the epidemiology and antimicrobial resistance patterns of BSIs in a pediatric tertiary care setting.
  • To analyze trends over an 11-year period in a US children's hospital.
  • To compare findings with existing data from adult populations.

Main Methods:

  • Retrospective analysis of positive blood cultures from a large children's hospital over 11 years.
  • Inclusion of monomicrobial bacteremia episodes; exclusion of repeat cultures and polymicrobial infections.
  • Identification of causative organisms and assessment of antimicrobial susceptibility patterns.

Main Results:

  • 8196 unique monomicrobial bacteremia episodes identified in 5508 patients.
  • Gram-positive bacteria (72%) and Gram-negative bacteria (22%) were predominant; Coagulase-negative Staphylococcus was most common.
  • ESKAPE pathogens comprised 20% of episodes; notable absence of vancomycin/linezolid resistance in S. aureus and favorable resistance profiles for key pathogens, though methicillin-resistant S. aureus (MRSA) rates increased.

Conclusions:

  • Gram-positive bacteria and ESKAPE pathogens are primary causes of bacteremia in hospitalized children.
  • Pediatric BSI antimicrobial resistance patterns appear more favorable than in adults, but require continued monitoring.
  • Multicenter surveillance is essential to detect emerging antimicrobial resistance trends in pediatric populations.
Abstract

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
78
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
372
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
29
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
702
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
461